1. Cancer Biology
Download icon

Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing

  1. Francesca Maria Bosisio  Is a corresponding author
  2. Asier Antoranz  Is a corresponding author
  3. Yannick van Herck
  4. Maddalena Maria Bolognesi
  5. Lukas Marcelis
  6. Clizia Chinello
  7. Jasper Wouters
  8. Fulvio Magni
  9. Leonidas Alexopoulos
  10. Marguerite Stas
  11. Veerle Boecxstaens
  12. Oliver Bechter
  13. Giorgio Cattoretti
  14. Joost van den Oord
  1. KU Leuven and UZ Leuven, Belgium
  2. ProtATonce Ltd, Greece
  3. Università degli studi di Milano-Bicocca, Italy
  4. KU Leuven, Belgium
Research Article
  • Cited 2
  • Views 1,127
  • Annotations
Cite this article as: eLife 2020;9:e53008 doi: 10.7554/eLife.53008

Abstract

In melanoma, the lymphocytic infiltrate is a prognostic parameter classified morphologically into 'brisk', 'non-brisk' and 'absent' entailing a functional association that has never been proved. Recently, it has been shown that lymphocytic populations can be very heterogeneous, and that anti-PD-1 immunotherapy supports activated T cells. Here, we characterize the immune landscape in primary melanoma by high-dimensional single cell multiplex analysis in tissue sections (MILAN technique) followed by image analysis, RT-PCR and shotgun proteomics. We observed that the brisk and non-brisk patterns are heterogeneous functional categories that can be further sub-classified into active, transitional or exhausted. The classification of primary melanomas based on the functional paradigm also shows correlation with spontaneous regression, and an improved prognostic value when compared to that of the brisk classification. Finally, the main inflammatory cell subpopulations that are present in the microenvironment associated with activation and exhaustion and their spatial relationships are described using neighbourhood analysis.

Article and author information

Author details

  1. Francesca Maria Bosisio

    Laboratory of Translational Cell and Tissue Research and Pathology Department, KU Leuven and UZ Leuven, Leuven, Belgium
    For correspondence
    f.bosisio1@gmail.com
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8874-2003
  2. Asier Antoranz

    National Technical University of Athens, ProtATonce Ltd, Athens, Greece
    For correspondence
    asierantoranz91@gmail.com
    Competing interests
    Asier Antoranz, Asier Antoranz is affiliated with ProtATonce Ltd. The author has no other competing interests to declare.
  3. Yannick van Herck

    Laboratory of Experimental Oncology, KU Leuven and UZ Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
  4. Maddalena Maria Bolognesi

    Department of Medicine and Surgery, Università degli studi di Milano-Bicocca, Milan, Italy
    Competing interests
    Maddalena Maria Bolognesi, Maddalena Maria Bolognesi has received funding from GlaxoSmithKline . The author has no other competing interests to declare.
  5. Lukas Marcelis

    Laboratory of Translational Cell and Tissue Research and Pathology Department, KU Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5446-1801
  6. Clizia Chinello

    Department of Medicine and Surgery, Università degli studi di Milano-Bicocca, Milan, Italy
    Competing interests
    No competing interests declared.
  7. Jasper Wouters

    Laboratory of Translational Cell and Tissue Research and Pathology Department, KU Leuven and UZ Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7129-2990
  8. Fulvio Magni

    Department of Medicine and Surgery, Università degli studi di Milano-Bicocca, Milan, Italy
    Competing interests
    No competing interests declared.
  9. Leonidas Alexopoulos

    National Technical University of Athens, ProtATonce Ltd, Athens, Greece
    Competing interests
    No competing interests declared.
  10. Marguerite Stas

    Department of Surgical Oncology, KU Leuven and UZ Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
  11. Veerle Boecxstaens

    Department of Surgical Oncology, KU Leuven and UZ Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
  12. Oliver Bechter

    Laboratory of Experimental Oncology, KU Leuven and UZ Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
  13. Giorgio Cattoretti

    Department of Medicine and Surgery, Università degli studi di Milano-Bicocca, Milan, Italy
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3799-3221
  14. Joost van den Oord

    Laboratory of Translational Cell and Tissue Research and Pathology Department, KU Leuven and UZ Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.

Funding

Horizon 2020 Framework Programme (642295)

  • Francesca Maria Bosisio

Horizon 2020 Framework Programme (675585)

  • Asier Antoranz

BEL114054 (HGS1006-C1121)

  • Maddalena Maria Bolognesi

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Ethical approval was obtained from the Ethical Committee/IRB OG032 of the University Hospital of Leuven. After the approval, the study was identified with the number S57266. According to the Clinical Trial regalement no informed consent was needed due to the use of post-diagnostic left-over material.

Reviewing Editor

  1. C Daniela Robles-Espinoza, International Laboratory for Human Genome Research, Mexico

Publication history

  1. Received: October 23, 2019
  2. Accepted: February 14, 2020
  3. Accepted Manuscript published: February 14, 2020 (version 1)
  4. Version of Record published: February 25, 2020 (version 2)

Copyright

© 2020, Bosisio et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,127
    Page views
  • 182
    Downloads
  • 2
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Cancer Biology
    2. Immunology and Inflammation
    Biancamaria Ricci et al.
    Research Article

    Cancer-associated fibroblasts (CAFs) are a heterogeneous population of mesenchymal cells supporting tumor progression, whose origin remains to be fully elucidated. Osterix (Osx) is a marker of osteogenic differentiation, expressed in skeletal progenitor stem cells and bone-forming osteoblasts. We report Osx expression in CAFs and by using Osx-cre;TdTomato reporter mice we confirm the presence and pro-tumorigenic function of TdTOSX+ cells in extra-skeletal tumors. Surprisingly, only a minority of TdTOSX+ cells expresses fibroblast and osteogenic markers. The majority of TdTOSX+ cells express the hematopoietic marker CD45, have a genetic and phenotypic profile resembling that of tumor infiltrating myeloid and lymphoid populations, but with higher expression of lymphocytic immune suppressive genes. We find Osx transcript and Osx protein expression early during hematopoiesis, in subsets of hematopoietic stem cells and multipotent progenitor populations. Our results indicate that Osx marks distinct tumor promoting CD45- and CD45+ populations and challenge the dogma that Osx is expressed exclusively in cells of mesenchymal origin.

    1. Cancer Biology
    Joana G Marques et al.
    Research Article

    The NuRD complex subunit CHD4 is essential for fusion-positive rhabdomyosarcoma (FP-RMS) survival, but the mechanisms underlying this dependency are not understood. Here, a NuRD-specific CRISPR screen demonstrates that FP-RMS is particularly sensitive to CHD4 amongst the NuRD members. Mechanistically, NuRD complex containing CHD4 localizes to super-enhancers where CHD4 generates a chromatin architecture permissive for the binding of the tumor driver and fusion protein PAX3-FOXO1, allowing downstream transcription of its oncogenic program. Moreover, CHD4 depletion removes HDAC2 from the chromatin, leading to an increase and spread of histone acetylation, and prevents the positioning of RNA Polymerase 2 at promoters impeding transcription initiation. Strikingly, analysis of genome-wide cancer dependency databases identifies CHD4 as a general cancer vulnerability. Our findings describe CHD4, a classically defined repressor, as positive regulator of transcription and super-enhancer accessibility as well as establish this remodeler as an unexpected broad tumor susceptibility and promising drug target for cancer therapy.